Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort

Radiotherapy and Oncology

Volumn 121, Issue 3, 2016, Pages 381-386

  Blanchard, Pierre ^a,b   Wong, Andrew J ^a   Gunn, G Brandon ^a   Garden, Adam S ^a   Mohamed, Abdallah S R ^a   Rosenthal, David I ^a   Crutison, Joseph ^a   Wu, Richard ^a   Zhang, Xiaodong ^a   Zhu, X Ronald ^a   Mohan, Radhe ^a   Amin, Mayankkumar V ^a   Fuller, C David ^a   Frank, Steven J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Radiation Oncology ^*  (France)

Author keywords

Head and neck cancer; Intensity modulated proton therapy; Late toxicity; Model; Prediction; Radiation therapy

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DYSPHAGIA; EXTERNAL VALIDITY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOTHYROIDISM; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MODEL; NORMAL TISSUE COMPLICATION; PATIENT SELECTION; PHOTON; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROTON THERAPY; RADIATION DOSE; RADIATION INJURY; RADIOTHERAPY PLANNING SYSTEM; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION STUDY; XEROSTOMIA; ADVERSE EFFECTS; AGED; DEGLUTITION DISORDERS; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MUCOSITIS; PATHOLOGY; PROCEDURES; RADIATION INJURIES; RADIOMETRY; RECEIVER OPERATING CHARACTERISTIC; THEORETICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DEGLUTITION DISORDERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; MODELS, THEORETICAL; MUCOSITIS; PATIENT SELECTION; PHOTONS; PROBABILITY; PROSPECTIVE STUDIES; PROTON THERAPY; RADIATION INJURIES; RADIOMETRY; RADIOTHERAPY, INTENSITY-MODULATED; ROC CURVE; XEROSTOMIA; YOUNG ADULT;

EID: 84994759808     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.08.022     Document Type: Article

References (27)

1. [1] Frank, S.J., Cox, J.D., Gillin, M., Mohan, R., Garden, A.S., Rosenthal, D.I., et al. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. Int J Radiat Oncol Biol Phys 89 (2014), 846–853, 10.1016/j.ijrobp.2014.04.019.
2. [2] Cox, J.D., Impediments to comparative clinical trials with proton therapy. Int J Radiat Oncol 95 (2016), 4–8, 10.1016/j.ijrobp.2015.09.036.
3. [3] Langendijk, J.A., Lambin, P., De Ruysscher, D., Widder, J., Bos, M., Verheij, M., Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 107 (2013), 267–273, 10.1016/j.radonc.2013.05.007.
4. [4] Lievens, Y., Pijls-Johannesma, M., Health economic controversy and cost-effectiveness of proton therapy. Semin Radiat Oncol 23 (2013), 134–141, 10.1016/j.semradonc.2012.11.005.
5. [5] Ramaekers, B.L.T., Grutters, J.P.C., Pijls-Johannesma, M., Lambin, P., Joore, M.A., Langendijk, J.A., Protons in head-and-neck cancer: bridging the gap of evidence. Int J Radiat Oncol 85 (2013), 1282–1288, 10.1016/j.ijrobp.2012.11.006.
6. [6] Widder, J., van der Schaaf, A., Lambin, P., Marijnen, C.A.M., Pignol, J.-P., Rasch, C.R., et al. The quest for evidence for proton therapy: model-based approach and precision medicine. Int J Radiat Oncol 95 (2016), 30–36, 10.1016/j.ijrobp.2015.10.004.
7. [7] Jakobi, A., Bandurska-Luque, A., Stützer, K., Haase, R., Löck, S., Wack, L.-J., et al. Identification of patient benefit from proton therapy for advanced head and neck cancer patients based on individual and subgroup normal tissue complication probability analysis. Int J Radiat Oncol Biol Phys 92 (2015), 1165–1174, 10.1016/j.ijrobp.2015.04.031.
8. [8] Bhide, S.A., Gulliford, S., Schick, U., Miah, A., Zaidi, S., Newbold, K., et al. Dose-response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. Radiother Oncol 103 (2012), 88–91, 10.1016/j.radonc.2011.12.027.
9. [9] Wopken, K., Bijl, H.P., van der Schaaf, A., van der Laan, H.P., Chouvalova, O., Steenbakkers, R.J.H.M., et al. Development of a multivariable normal tissue complication probability (NTCP) model for tube feeding dependence after curative radiotherapy/chemo-radiotherapy in head and neck cancer. Radiother Oncol 113 (2014), 95–101, 10.1016/j.radonc.2014.09.013.
10. [10] Christianen, M.E.M.C., Schilstra, C., Beetz, I., Muijs, C.T., Chouvalova, O., Burlage, F.R., et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. Radiother Oncol 105 (2012), 107–114, 10.1016/j.radonc.2011.08.009.
11. [11] Boomsma, M.J., Bijl, H.P., Christianen, M.E.M.C., Beetz, I., Chouvalova, O., Steenbakkers, R.J.H.M., et al. A prospective cohort study on radiation-induced hypothyroidism: development of an NTCP model. Int J Radiat Oncol Biol Phys 84 (2012), e351–e356, 10.1016/j.ijrobp.2012.05.020.
12. [12] Beetz, I., Schilstra, C., van der Schaaf, A., van den Heuvel, E.R., Doornaert, P., van Luijk, P., et al. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother Oncol 105 (2012), 101–106, 10.1016/j.radonc.2012.03.004.
13. [13] Gunn, G.B., Blanchard, P., Garden, A.S., Zhu, X.R., Fuller, C.D., Mohamed, A.S., et al. Clinical outcomes and patterns of disease recurrence after intensity modulated proton therapy for oropharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 95 (2016), 360–367, 10.1016/j.ijrobp.2016.02.021.
14. [14] Rosenthal, D.I., Asper, J.A., Barker, J.L., Garden, A.S., Chao, K.S.C., Morrison, W.H., et al. Importance of patient examination to clinical quality assurance in head and neck radiation oncology. Head Neck 28 (2006), 967–973, 10.1002/hed.20446.
15. [15] Chronowski, G.M., Garden, A.S., Morrison, W.H., Frank, S.J., Schwartz, D.L., Shah, S.J., et al. Unilateral radiotherapy for the treatment of tonsil cancer. Int J Radiat Oncol Biol Phys 83 (2012), 204–209, 10.1016/j.ijrobp.2011.06.1975.
16. [16] Lomax, A.J., Intensity modulated proton therapy and its sensitivity to treatment uncertainties 1: the potential effects of calculational uncertainties. Phys Med Biol 53 (2008), 1027–1042, 10.1088/0031-9155/53/4/014.
17. [17] Lomax, A.J., Intensity modulated proton therapy and its sensitivity to treatment uncertainties 2: the potential effects of inter-fraction and inter-field motions. Phys Med Biol 53 (2008), 1043–1056, 10.1088/0031-9155/53/4/015.
18. [18] Zhu, X.R., Li, Y., Mackin, D., Li, H., Poenisch, F., Lee, A.K., et al. Towards effective and efficient patient-specific quality assurance for spot scanning proton therapy. Cancers 7 (2015), 631–647, 10.3390/cancers7020631.
19. [19] Brouwer, C.L., Steenbakkers, R.J.H.M., Bourhis, J., Budach, W., Grau, C., Grégoire, V., et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol 117 (2015), 83–90, 10.1016/j.radonc.2015.07.041.
20. [20] Mohamed, A.S.R., Ruangskul, M.-N., Awan, M.J., Baron, C.A., Kalpathy-Cramer, J., Castillo, R., et al. Quality assurance assessment of diagnostic and radiation therapy-simulation CT image registration for head and neck radiation therapy: anatomic region of interest-based comparison of rigid and deformable algorithms. Radiology 274 (2015), 752–763, 10.1148/radiol.14132871.
21. [21] Dale, T., Hutcheson, K., Mohamed, A.S.R., Lewin, J.S., Gunn, G.B., Rao, A.U.K., et al. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: dose–volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol 118 (2016), 304–314, 10.1016/j.radonc.2016.01.019.
22. [22] Kang, J., Schwartz, R., Flickinger, J., Beriwal, S., Machine learning approaches for predicting radiation therapy outcomes: a clinician's perspective. Int J Radiat Oncol Biol Phys 93 (2015), 1127–1135, 10.1016/j.ijrobp.2015.07.2286.
23. [23] Thaker, N.G., Frank, S.J., Feeley, T.W., Comparative costs of advanced proton and photon radiation therapies: lessons from time-driven activity-based costing in head and neck cancer. J Comp Eff Res 4 (2015), 297–301, 10.2217/cer.15.32.
24. [24] Beetz, I., Schilstra, C., van Luijk, P., Christianen, M.E.M.C., Doornaert, P., Bijl, H.P., et al. External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiother Oncol 105 (2012), 94–100, 10.1016/j.radonc.2011.11.006.
25. [25] Lambin, P., Zindler, J., Vanneste, B.G.L., De Voorde, L.V., Eekers, D., Compter, I., et al. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev, 2016, 10.1016/j.addr.2016.01.006.
26. [26] List, M.A., Stracks, J., Colangelo, L., Butler, P., Ganzenko, N., Lundy, D., et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment?. J Clin Oncol 18 (2000), 877–884.
27. [27] Porter, M.E., What is value in health care?. N Engl J Med 363 (2010), 2477–2481, 10.1056/NEJMp1011024.